The U.S. Food and Drug Administration (FDA) has approved a new drug, Toviaz (fesoterodine fumarate), to help patients suffering from overactive bladder (OAB).
The new medication works by relaxing the smooth muscle tissue of your bladder. This reduces urinary frequency, urge to urinate, and sudden urinary incontinence (leakage of urine), that are common symptoms of OAB.
If you have overactive bladder you may be facing issues that can hamper your ability to enjoy life to its fullest. Toviaz may provide an additional treatment option to help you manage your OAB symptoms.
Other medications that relax the bladder and are used to treat OAB include:
- Detrol (tolterodine)
- Ditropan (oxybutynin)
- Enablex (darifenacin)
- Oxytrol (oxybutynin)
- Sanctura (trospium)
- VESIcare (solifenacin)